Almac Group Announces Support of Agios' PYRUKYND®

Article

Almac Group confirms it has supported Agios Pharmaceuticals, Inc., in the clinical trial and commercial launch of PYRUKYND® (mitapivat).

The treatment is the first FDA approved, disease-modifying therapy for adults with hemolytic anemia caused by PK deficiency, a rare, debilitating, and lifelong form of anemia.

Read more about the work between Almac Group and Agios here.

Recent Videos
John Arena
James Foster
Navigating an Uncertain Regulatory Landscape
James Foster
Related Content